Seattle Genetics Chief Executive Officer, Clay Siegall, enjoys sharing interesting and informative articles on his official blog. An article he recently shared was one from NPR that was about how urgent it is that global warming is addressed in order to save coral reefs around the world. The article describes how a mass bleaching event happened in 2016 which destroyed an enormous amount of the Great Barrier Reef in Australia. Researchers discovered that less than 9% of coral reefs that make up the Great Barrier Reef avoided any bleaching. This event was even worse than the bleaching events that occurred in 1998 and 2002.
Another article that Clay Siegall has shared was another NPR article that discussed how to get farmers to use cover crops. Cover crops are grown on fields after it has been harvested. The use of cover crops is environmentally friendly as they hold soil in place and hold nutrients and chemical in place rather than their leaching into nearby rivers and streams. Unfortunately, the vast majority of farmers don’t make use of them. A study has found a way to get farmers to make use of cover crops, though – pay them. They’re willing to go to the effort and expense of using cover crops if they’re paid for it.
Siegall founded Seattle Genetics in 1998 after having been involved in research and development for several years. In addition to CEO, he is also the President and Chairman of the Board. Seatle Genetics is focused on finding cures for cancer and researches how anitbody-drug conjugates can be used as an effective therapy. Dr. Seigall has led one drug to market, Adcetris, which is a drug therapy for two forms of Hodgkin Lymphoma. This drug is now used throughout the United States, Canada, and other parts of the world.
As the head of Seattle Genetics, Clay Siegall leads the overall strategy of the company, its research and development activities, and oversees its day-to-day activities. He also forms the strategic partnerships that Seattle Genetics has formed with other pharmaceutical companies including Pfizer, AbbVie, and GlaxoSmithKline.